Content Tagged “Mark Atkinson”
Published: Jun 2nd, 2015
Members from The University of Florida Diabetes Institute recently presented their research findings at the ADA’s 75th Scientific Sessions Meeting in Boston. More than 40 UF physicians, researchers, graduate students, and faculty took part in this year’s programming. Read more.
Published: Apr 8th, 2015
Diamyd Medical, a Swedish medical research company, annouced that it will join a research initiative launched by JDRF aimed at increasing the understanding of the natural progression of type 1 diabetes in order to transform and accelerate drug development for the disease. Diamyd Medical will contribute data that will be made available to industry and academia partners through an open access database together with similar data from other late stage type 1 diabetes studies.
Published: Feb 4th, 2015
Mark A. Atkinson, PhD., director of the University of Florida Diabetes Institute, and Alberto Pugliese, M.D., head of the Immunogenetics Program at the University of Miami’s Diabetes Research Institute, were recently honored with the JDRF Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award on behalf of the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD). Learn more.
Published: Jan 30th, 2015
Researchers at the University of Florida Diabetes Institute and University of Miami Diabetes Research Institute will share a new $3.3 million collaborative grant awarded by The Leona M. and Harry B. Helmsley Charitable Trust that will help fast-track significant discoveries in Type 1 diabetes worldwide. Read more.
Published: Dec 23rd, 2014
Benjamin Keselowsky, Ph.D. has received a new NIH R01 grant for “Biomaterial Delivery System for Type 1 Diabetes Vaccine”. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases in collaboration with UF Diabetes Institute Director, Mark Atkinson, Ph.D., and Clive Wasserfall, this, $1.5M grant will fund the investigation of biodegradable microparticle/hydrogel formulations delivering immuno-modulatory factors to targeted immune cell types for the prevention and reversal of T1D.
Published: Nov 14th, 2014
Combining Efforts to Stop Diabetes® Nearly 30 million Americans have diabetes and an additional 86 million have prediabetes, placing them at risk for developing Type 2 diabetes. The University of Florida and […]
Published: Oct 8th, 2014
In 2013, the global prevalence of diabetes was estimated at 382 million. By 2035, the number is expected to reach 592 million. The International Diabetes Federation (IDF) estimates that 8.3% […]
Published: Jul 11th, 2014
A new study co-authored by University of Florida diabetes researchers finds that bacteria in the guts of young children with type 1 diabetes are different from those of other kids. The research is helping clarify the importance of healthy gut bacteria development in early childhood and could help lead to novel prevention therapies for people at risk of developing the disease.
Published: Jun 30th, 2014
UF Diabetes Institute co-directors Mark Atkinson, PhD and Desmond Schatz, MD, are recognized as global leading authorities in the field of Type 1 diabetes mellitus. Together, their preeminent research contributions are shedding light on promising new therapies to treat and prevent this disease. Learn more about this outstanding achievement.
Published: Jun 21st, 2014
UF and UF Health faculty, postdoctoral fellows, and graduate students submitted a record number of original research presentations for the American Diabetes Association’s 74th Scientific Sessions held June 13-17, 2014 at the Moscone Center in San Francisco, California. This year’s submissions represent one of the largest showcases of research emanating from UF.